A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

NCT05282953

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Kiora Pharmaceuticals, Inc.
Enrollment	48 participants

Key Eligibility Criteria

Inclusion (22)

- Main Study:
- Be aged 18 to 80 years at Visit 1 of either sex and of any race.
- Be willing and able to provide informed consent either written, or if the Participant is not able to read, provide consent as stipulated by local laws and Human Research Ethics Committee (HREC) guidelines.
- Be willing and able to follow all instructions and attend all study visits.
- Have a clinical diagnosis of retinitis pigmentosa (Cohorts 1 - 3) or choroideremia (Cohort 3 only).

... and 17 more (see full listing online)

Exclusion (18)

- Have evidence of material/substantial optic nerve disease.
- Have a history of retinal detachments.
- Have clinically significant ocular disease (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study or clinically significant opacities of the media.
- Have high intraocular pressure (IOP) \>22 mm Hg.
- Have had a previous intraocular surgery (excluding phakocataract surgery).

... and 13 more (see full listing online)

Locations (3 total)

Save Sight Institute, Sydney, New South Wales, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Harley Eye Clinic, North Adelaide, South Australia, Australia

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.